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[57] ABSTRACT 
Viral, endoparasitoid and/or host genes that speci?cally 
inhibit the immune response of insect pests, useful for 
broadening the host range of insect viruses. Symbiont 
viruses of insect pests are genetically modi?ed to express 
immune-suppressing proteins or biologically active frag 
ments thereof and, optionally toxins, to increase the virus 
host range and/or improve the efficacy of insect pathogens. 
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VIRAL AND INSECT GENES THAT INHIBIT 
THE IMMUNE SYSTEM AND METHODS OF 
USE THEREOF 
GOVERNMENT LICENSE RIGHTS 
The US. Government has a paid-up license in this inven 
tion and the right in limited circumstances to require the 
patent oWner to license others on reasonable terms as 
provided for by the terms of Grant No. AI-33114-03 
aWarded by the National Institutes of Health, Department of 
Human Services. 
FIELD OF THE INVENTION 
The invention relates to the neW genes, particularly viral, 
endoparasitic insect and insect host genes, encoding prod 
ucts that speci?cally inhibit the insect immune response. The 
invention further relates to methods of expanding the host 
range of insect viruses and methods of biological control of 
plant insect pests using the genes of the invention. The 
invention is thus useful, for example, in the biological 
control of insect pests and, in particular, in the protection of 
crops from insect damage. 
BACKGROUND OF THE INVENTION 
Insects, like other animals, have effective immune sys 
tems to combat both biotic and abiotic foreign invasion. It is 
of interest, then, that certain insect species, the endoparasitic 
insects, spend a part of their life cycle inside the body of 
other insect hosts. Considerable effort has been expended 
investigating the mechanism by Which these endoparasitic 
insects avoid the host immune system in this parasitic 
relationship. 
Mechanisms of “immune evasion” include (1) avoidance 
(e. g., by not coming into prolonged contact With the immune 
system), (2) evading the immune system, for example, by 
molecular mimicry, (3) blocking the immune recognition 
system, (4) subversion of the host immune system, and (5) 
suppression of the immune system. (Vinson, UCLA Sym 
posia on Molecular and Cellular Biology, 112: 517 (1990)). 
For large foreign bodies, in particular, encapsulation by the 
granulocytes and plasmatocytes of the hemolymph is a 
common immune response. 
It is currently thought that encapsulation results from a 
?rst recognition of the foreign body surface by the 
granulocytes, Which then degranulate to release one or more 
chemoattractant substances that are assumed to attract addi 
tional granulocytes and plasmatocytes. The plasmatocytes 
then attach to the foreign body, ?atten out and form a 
microtubule and micro?lament matrix, ultimately enclosing 
the foreign body in several layers of cells. In some cases, the 
inner layers of plasmatocytes melaniZe. Encapsulation thus 
serves to isolate the foreign body in the insect. 
One Well characteriZed parasitoid-host system in Which 
there is immune system evasion is that of the endoparasitic 
Wasp Campoletis sonorensis and its host, the tobacco bud 
Worm Heliothis virescens. In investigating hoW immuno 
suppression is regulated in this system, it became apparent 
that a group of Wasp viruses, knoWn generically as 
polydnaviruses, play a role in the suppression of the host 
immune system. It is believed that during oviposition, the 
endoparasitic insect, for example C. sonorensis, injects not 
only eggs but also polydnavirus and oviduct proteins. 
Shortly thereafter, the host insect immune system begins to 
shoW evidence of altered activity and the endoparasitoid 
eggs remain free from encapsulation. The precise mecha 
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nism of this immune suppression is not, hoWever, presently 
knoWn but may involve disruption of the hemocyte cytosk 
eleton. 
Additional factors in immune system suppression may be 
contained in the Wasp oviduct ?uid and venom. It is also 
knoWn that insect venom, ovarian and viral proteins share 
certain epitopes and that one or more ovarian proteins 
transiently inhibits the immune response (Webb and 
Luckhart, Archives of Insect Biochemistry and Physiology, 
26: 147 (1994)). 
It has been shoWn that oviduct proteins may, at least in 
part, mediate the immunosuppressive effect observed in 
some systems. Additionally, the effect can be generated by 
the injection of puri?ed polydnavirus particles and virus-like 
particles (VLPs). For example, VLPs (Which are devoid of 
nucleic acids) are thought to be involved in the suppression 
of the immune response in Venturia cansecens. (Schmidt et 
al., Subcell. Biochem., 15: 91 (1989)). Certain VLP proteins 
may be related to a host protein, designated p42, in this 
system. Another report indicates interference of 
plasmatocyte-dependent immune phenomena by 
polydnavirus-rich calyx ?uid. (Davies et al., Cell and Tissue 
Research, 251: 467 (1988)) It is conjectured that successful 
parasitism may require immunosuppression of the host to a 
level that interferes With other cellular immune reactions in 
addition to encapsulation. 
Host cellular factors may also be involved in the immune 
suppression in some cases. For example, a cellular immu 
nosuppressive protein factor, ISP, has been isolated from the 
larval plasma of the armyWorm Pseua'aletia separata para 
sitiZed With the Wasp Cotesia kariyai. The factor, Which 
suppresses encapsulation of foreign bodies, is suggested to 
be a 470 kDa hexamer composed of identical 82 kDa 
subunits. (HayakaWa, J. Biol. Chem., 269:14536 (1994)). 
Thus, depending upon the particular system studied, host, 
parasite and/or virus factors may be involved in the sup 
pression of the host immune system. (Vinson, Archives of 
Insect Biochemistry and Physiology, 13: 1 (1990)). It is 
therefore believed that each of these sources may play a role 
in host insect immune system suppression generally, and that 
there may be a cooperative effect betWeen factors Which 
alloW the immune system to be compromised suf?ciently for 
parasitiZation. 
The WHv1.0, WHv1.6 and VHv1.1 genes of Campoletis 
sonorensis polydnavirus (CsPDV) have recently been 
cloned and sequenced. These genes are described as mem 
bers of a polydnavirus “cysteine-rich” gene family. (Dib 
Hajj et al., Proc. Natl. Acad. Sci. (USA) 90: 3765 (1993)). 
It has been conjectured that these genes may play a role in 
preventing the recognition of foreign objects and/or the 
normal response of components of the immune system. 
(Summers et al., Proc. Natl. Acad. Sci. (USA) 92: 29 
(1995)). Indeed, the VHv1.1 gene product of the C. sono 
rensis polydnavirus has been implicated in the inhibition of 
the cellular immune response. This 30 kDa protein is shoWn 
by indirect immuno?uorescence to bind both granulocytes 
and plasmatocytes and is thought to inhibit encapsulation. 
(Li et al., J. Virol., 68: 7482 (1994)). 
As parasitoid insects eventually kill their insect hosts, the 
parasitoids represent a natural biological means for control 
ling insect pests, in particular those pests responsible for 
crop damage. Traditionally, such parasitoids have not pro 
vided a highly effective strategy for insect control, in large 
part because the host range of the parasitoids is limited. 
It Would therefore be advantageous to provide methods 
Whereby the host range of parasitoid insects could be 
5,827,518 
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broadened, such that the parasitoids Would provide effective 
biological control for a larger number of insect hosts. 
It Would be a further advantage to identify speci?c virus, 
parasitoid and/or host genes involved in the successful 
suppression of the insect immune system by the endopara 
sitoid. Such genes could then be used, through recombinant 
DNA techniques, to generate genetically modi?ed insects, 
viruses and/or plants, that express one or more immune 
suppressing factors. 
The invention provides these and other advantages, as 
Will be apparent to those skilled in the art based on the 
disclosure hereunder. 
SUMMARY OF THE INVENTION 
The invention ?rst provides a DNA useful for the sup 
pression of an insect host immune system. In particular, the 
invention provides the VHv1.4 genomic DNA, derived from 
the C. sonorensis polydnavirus, and the sequence of Which 
is set forth in SEQ ID NO: 1. The invention further provides 
a VHv1.4 cDNA (SEQ ID NO: 2), Which encodes the 
VHv1.4 protein product (SEQ ID NO: 3) involved in insect 
immune system suppression. The invention also provides 
the SOPs cDNA (SEQ ID NO: 4) of Campoletis sonorensis 
and the protein encoded thereby (SEQ ID NO: 5), also useful 
in suppressing the insect immune system in the methods of 
the invention. Each of these DNAs and protein is useful for 
the expansion of viral host range. 
The invention further provides methods for expanding 
parasitoid insect host range comprising: 
providing one or more DNAs encoding an insect immune 
suppressing factor, or a biologically active fragment 
thereof, operably linked to one or more expression 
signals, 
inserting said DNA into the genome of an endoparasitic 
insect virus, an endoparasitoid or a plant, and 
expressing said DNA to provide for immune suppression 
of one or more insect hosts, 
Wherein the insect hosts are not a natural host for said 
endoparasitic insect. 
The invention additionally provides for genetically modi 
?ed viruses, particularly polydnaviruses, endoparasitoid 
insects and/or plants capable of expressing a DNA encoding 
an immunosuppressive protein or polypeptide. 
The invention also provides plasmids, vectors and, 
especially, expression vectors operably linked to the DNA of 
the invention. 
The invention yet further provides a recombinant protein 
encoded by a DNA, or biologically active fragments thereof, 
Wherein said protein or fragment suppresses the immune 
system of one or more insect hosts, as Well as methods of 
broadening the host range of insect viruses and parasitoids 
comprising applying the protein or fragment to plants, 
Whereby said protein is ingested by said pests. 
The invention further provides methods of protecting 
crops, particularly commercially important crops, from 
damage by one or more insect pests. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts the genomic DNA sequence of the C. 
sonorensis polydnavirus VHv1.4 DNA (SEQ ID NO: 1). 
FIG. 2 depicts the predicted amino acid sequence (SEQ 
ID NO: 3) encoded by the VHv1.4 cDNA sequence (SEQ ID 
NO: 2). 
FIG. 3 depicts the C. sonorensis SOPs cDNA SEQ ID 
NO: 4 and the protein product (SEQ ID NO: 5) encoded 
thereby. 
FIG. 4 schematically depicts the plasmid pSH V. 
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DETAILED DESCRIPTION OF THE 
INVENTION 
Genes that disrupt the insect immune system are of 
practical importance in the area of biological pest control. 
Speci?cally, the insect immune system is thought to deter 
mine the host range of the group of insect viruses knoWn as 
baculoviruses. Additionally, virus host range is a major 
factor in determining Whether a particular virus Will be of 
commercial importance. Genes that suppress the immune 
system and thereby expand the virus host range Would 
signi?cantly improve the commercial prospects and perfor 
mance of insect viruses as a biological pest control means. 
Immune suppressive genes under the invention provide for 
methods in Which viruses, for example baculoviruses, can be 
used for expression, With the concomitant immune suppres 
sion and expansion of the virus host range. 
The endoparasitic Wasp Campoletis sonorensis injects a 
polydnavirus into its host Heliothis virescens during ovipo 
sition. Viral gene expression protects the Wasp egg and larva 
from encapsulation by host hemocytes. The invention relates 
to the isolation and puri?cation of genes involved in escap 
ing the host immune response. As exemplary of the 
invention, the VHv1.4 genomic and cDNA have been iso 
lated from C. sonorensis polydnavirus. As shoWn beloW, the 
VHv1.4 protein is involved in suppressing the immune 
system of the insect host. This protein is further capable, by 
means of its immune system targeting function, to broaden 
the host range of the endoparasite and thereby provide an 
ef?cient means of pest control. 
The current data indicates that the binding of immune 
suppressing proteins to granulocytes and plasmatocyte sur 
faces is involved in immune suppression and disruption of 
the hemocyte cytoskeleton. The binding of hemocytes has 
been shoWn to occur in permissive and semi-permissive 
hosts. Moreover, the binding additionally occurs in some, 
but not all, non-permissive hosts. These results suggest that 
the host range of endoparasitic insects is related to the 
effectiveness by Which these insects suppress the immune 
system of the potential host. 
EXPERIMENTAL 
A. Isolation of the VHv1.4 cDNA 
Insect rearing and viral DNA puri?cation from calyx ?uid 
Were done as described (Krell et al., J. Virol. 43: 859 
(1982)). For RNA analysis requiring parasitiZed H. 
virescens, 15 to 20 third-instar larvae Were parasitiZed by 8 
to 10 female Wasps Within about 30 minutes. At the end of 
this period, larvae Were designated as 0 hr p.p (post 
parasitiZation). 
A lambda gt11 cDNA library Was constructed from 
mRNA of parasitiZed H. virescens and screened by colony 
hybridiZation using the VHv1.1 cDNA as a probe 
(Sambrook et al. 1989). Positive hybridiZation plaque DNA 
Was ampli?ed by polymerase chain reaction (PCR) 
using lambda gt11 forWard (5‘ 
GGTGGCGACGACTCCTGGAGC-3‘) (SEQ ID NO: 6) 
and reverse (5‘-GACACCAACTGGTAATG-3‘)) (SEQ ID 
NO: 7) primers (Tung et al. 1989). Ampli?cation reactions 
Were carried out in 1x PCR buffer (10 mM Tris-HCl, pH 9.0, 
50 mM KCl), With 50 pM each dNTPs, 1.25 mM MgCl2, 0.5 
pg of each of the primers, 5 pL phage suspension and 2.5 
units of Taq DNApolymerase. Phage DNA Was denatured at 
94° C. for 2 min. and 35 ampli?cation cycles Were per 
formed (94° C., 2 min., 55° C., 2 min., 72° C., 3 min.) in a 
Model 480 DNA thermocycler (Perkin Elmer Cetus). The 
ampli?ed DNA fragments Were digested With EcoRI and 
5,827,518 
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cloned in “BLUESCRIPT” II KS(—) (Stratagene) for 
sequence analysis. 
To clone the 3‘ end of VHv1.4 cDNA, 0.5 pg of total RNA 
from parasitiZed H. virescens larvae at 24 hr. p.p. Was 
reverse transcribed using oligo(dT) primer 
(GCACTTAACT17) (SEQ ID NO: 8). Reverse transcription 
Was performed at 42° C. for 30 min. in 20 pL of reaction mix 
containing 1>< cDNA synthesis buffer (50 mM Tris-HCl, pH 
8.9, 20 mM KCl, 2.5 mM MgCl2, 200 pM of each dNTP, 10 
mM DTT, 0.2 pg primer and 200 units MMLV reverse 
transcriptase (Promega)). The reaction mixture Was digested 
With 2 units of RNAse H at 42° C. for 10 min. One microliter 
of the reverse transcription mixture Was removed for PCR 
With oligo(dT) and 1.4 kb cDNA-speci?c primers, using 35 
cycles of 94° C., 1 min., 48° C., 1 min., 72° C., 2 min. The 
PCR product Was cloned in the pCR-TRAP vector 
(GeneHunter) for sequence analysis. 
B. Isolation of the VHv1.4 Genomic DNA 
The viral genomic copy of the VHv1.4 gene Was cloned 
from a 12.9 kb EcoRI fragment of SH V, contained in 
pVE12.9 cloned in pBS (Dib-Hajj et al. 1993). This clone 
Was used to screen a CsPDV PstI library in “BLUESCRIPT” 
KS(—) to select an overlapping 7.9 kb clone (pVP7.9) that 
hybridized to both termini of pVE12.9. Another CsPDV 
Sau3A library made from partially digested viral DNA Was 
probed With the 0.8 kb fragment of the 1.4 kb cDNA. Clones 
hybridiZing to the probe Were re-screened by PCR With 1.4 
kb-speci?c primers. Ampli?cation Was performed With the 
GeneAmp 6000 system (Perkin Elmer Cetus) using the 
folloWing protocol: 94° C., 2 min., 94° C., 30 sec., 55° C., 
30 sec., 72° C., 1 min., for 35 cycles. Overlapping SH V 
genomic clones Were mapped With restriction enZymes. 
E. DNA Sequencing and Analysis 
DNA sequences Were determined by the dideoxy chain 
termination method (Sanger et al. 1977) using “SEQUE 
NASE” 2.0 kit (United States Biochemical) . Sequence data 
Were analyZed using the University of Wisconsin Genetics 
Computer Group DNA analysis softWare for the VAX com 
puter (release 7.2). 
The predicted amino acid sequence of the longest ORF of 
the VHv1.4 cDNA insert is given (SEQ ID NO: 3). The 
cDNA sequence is 1338 bp long, and the longest ORF 
identi?ed is 966 nt from nucleotide 57 (relative to the 5‘ end 
of the cDNA clone) to nucleotide 1022. The sequence 
surrounding the ?rst methionine codon in the cDNA is 
consistent With the translation initiation consensus sequence 
(KoZak 1983). A putative polyadenylation signal is located 
15 nt upstream from the poly(A) tail. 
The longest ORF in the 1.4 kb cDNA encodes a protein 
of 322 amino acids With a predicted molecular mass of 42 
kDa. The N-terminal amino acid sequence is very hydro 
phobic and encodes a signal peptide according to the rules 
of von Heijne, indicating that this protein is destined either 
for insertion into the membrane or secretion. There are six 
potential N-glycosylation sites in the protein and, similar to 
the VHv1.1 cDNA, there are tWo complete cysteine motifs 
(amino acids 40 to 80 and 277 to 317). 
The genomic clone Was determined by Southern hybrid 
iZation to reside on a 2.7 kb XhoI genomic fragment. This 
2.7 kb fragment Was sequenced, con?rming that the cDNA 
is encoded by this genomic DNA fragment. Aputative TATA 
box is located in the genomic DNA 42 bp upstream of the 5‘ 
end of the cDNA clone. Four introns 124, 186, 187 and 342 
bp in length Were identi?ed in the genomic DNA. Splicing 
signals are consistent With the consensus for eukaryotic 
genes. Intron 1 is found in the 5‘ leader region, 27 bp 
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6 
upstream of the translation initiation ATG. The three other 
introns lie Within the coding sequence. 
F. Inhibition of the Immune Response by the VHv1.4 
Gene Product 
To demonstrate that the VHv1.4 gene product inhibits 
host immune response, the cDNA and genomic clone are 
inserted into bacterial expression vectors operably linked to 
transcription control signals. A suitable vector for such 
expression is pET22b(+), Which alloWs the fusion With a 6x 
histidine tag to facilitate puri?cation. Such construction is 
suitably made by attachment of, for example, EcoRI linkers 
to the VHv1.4 DNA and insertion into EcoRI site of the 
vector by standard procedures. The expressed product from 
the vector is thus a fusion that facilitates puri?cation. 
After transformation of a suitable bacterial host, (e.g. E. 
coli), expression of the fusion protein is induced With IPTG 
and puri?ed from the bacterial lysates. The fusion protein 
can be engineered, Where desired, to contain a unique 
protease cleavage site at the fusion junction. For example, a 
Factor Xa cleavage site may be used, alloWing isolation of 
intact or nearly intact VHv1.4 protein. As is knoWn to the 
skilled artisan, this puri?ed protein can also be used for 
immuniZation to raise antibodies against one or more anti 
genic determinants. 
The VHv1.4 cDNA or genomic DNA may also suitably be 
expressed in a baculovirus system. The recombinant DNA is 
cloned into a suitable vector, for example pVL1393, and 
cotransfected With the E2 strain of Autographa californica 
nuclear polyhedrosis virus into Spodoptera frugipera'a (Sf9) 
cells to produce a recombinant virus. This virus may then be 
assayed according to standard procedures (Webb et al. 
1990). 
To demonstrate the immunosuppressive function of the 
VHv1.4 protein, Washed eggs are prepared from 20 chilled 
C. sonorensis female Wasps. The eggs are suitably dissected 
from Wasp ovaries about 5 days after mating. Eggs are 
suspended in 1 mL of Pringle’s saline and collected by 
centrifugation (1500><g, 7 min.). Eggs are then resuspended 
in Pringle’s saline and pelleted about ?ve times to remove 
CsPDV and ovarian proteins. Recombinant virus (104 PFU) 
in a volume of about 1 pL is injected into chilled fourth 
instar H. virescens larvae With a 10 pL Hamilton microsy 
ringe. The E2 stain of Wild-type virus or a saline solution can 
be injected into additional larva as controls to Which the 
activity of the recombinant virus can be compared. Naturally 
parasitiZed insects may also be used as a control. 
TWenty four hours post injection, pretreated larvae are 
injected With Washed Wasp eggs (8 to 12 eggs/larva) With a 
?nely draWn glass capillary. The encapsulation response to 
the eggs is then determined. In the absence of virus and 
ovarian proteins, a strong encapsulation response to parasite 
eggs is seen at about 24 hours post injection. If, at 24 hours 
post parasitiZation, one or more of the eggs had 100 or more 
adherent hemocytes, covering at least one third of the egg, 
then the host is scored as immunoresponsive. If feWer than 
100 hemocytes are adhered on all the eggs recovered, then 
the insect is scored as immunosuppressed. These data can 
then be analyZed by chi-square statistical analysis. 
The above-described experiment demonstrates that the 
VHv1.4 protein inhibits the host immune response. Thus, 
vectors expressing the VHv1.4 protein, or biologically 
active fragments thereof, and other toxic proteins may be 
useful in biological pest control. For example, inclusion in 
the vector of an expression cassette for scorpion toxin and/or 
other toxins, coupled With the immune suppression of the 
pest, alloWs for a faster and more ef?cient kill of the pests. 
5,827,518 
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It is thus another embodiment of the invention to have a 
vector, preferably a baculovirus vector, containing a DNA 
Which encodes an immune-suppressing protein or fragment 
thereof, preferably the VHv1.4 cDNA, genomic DNA, or a 
biologically active fragment thereof, and one or more genes 
encoding a polypeptide or protein possessing a toxic activity. 
Asuitable vector for use in this embodiment of the invention 
is the above-mentioned pVL1393 baculovirus vector. 
Expression of the immune-suppressing sequences in a 
recombinant virus, a parasitoid, a host or a plant is used to 
affect biological control of the insect pest. 
In yet another embodiment of the invention, the VHv1.4 
cDNA, genomic DNA or biologically active fragment 
thereof, is introduced into plants to create transgenic plant 
varieties. Such plants, When producing the VHv1.4 protein 
or biologically active fragment thereof, become resistant to 
insect pests. According to this embodiment of the invention, 
a transgenic plant capable of expressing an immune sup 
pressing protein or polypeptide, is made by any of the 
knoWn techniques using the DNA of the invention. Insect 
larva feeding on such transgenic plants become immune 
suppressed and thus susceptible to a large variety of dis 
eases. 
A further embodiment of the invention is directed to use 
of the VHv1.4 protein, or a biologically active fragment 
thereof, for direct application onto plants. In this 
embodiment, the VHv1.4 protein is overexpressed, for 
example, in bacteria, yeast, plants, insect cells, etc., isolated 
and puri?ed. In one preferred embodiment, the protein or 
fragment thereof is produced as a fusion With an amino acid 
sequence that assists in puri?cation. Preferably, a poly 
histidine linker is used for a N- or C-terminal fusion product, 
thereby alloWing rapid isolation and puri?cation of the 
fusion protein. Most preferably, the poly-histidine linker 
comprises about 7 contiguous histidine residues and may be 
removed by endoproteolytic enZymatic cleavage. 
The recombinant protein so produced may be conve 
niently lyophiliZed to increase storage life or, as one 
alternative, may be kept in a buffered solution, for example, 
phosphate buffered saline. The product so produced is then 
applied to plants, preferably after reconstitution of the 
lyophiliZed product in Water or buffered saline. In practice, 
insect larva ingest the recombinant protein and become 
immune suppressed, thereafter being susceptible to lethal 
infections. 
As examples of other genes useful in the practice of the 
invention, mention is made to the C. sonorensis OPs 33 
genes, in particular the SoPs gene (SEQ ID NO: 4), and the 
C. sonorensis polydnavirus WHv1.0, WHv1.6, VHv1.1 and 
2.6 kb RNA genes, as Well as functionally related genes from 
virus, endoparasitoids and hosts. FolloWing the disclosure 
herein, other genes related to the above-mentioned genes can 
be isolated by, for example, library hybridiZation, PCR and 
reverse transcription technologies. Such genes are therefore 
meant to be embraced Within the scope of the present 
invention. 
The invention further is useful for increasing the host 
range of endoparasitic pests. In this embodiment, a recom 
binantly engineered virus, preferably a baculovirus, is con 
structed to express an immune suppressing protein, prefer 
ably VHv1.4 protein, or a biologically active fragment 
thereof. A variety of endoparasitic pests are then produced 
Which are capable of expressing the recombinant virus. 
Upon oviposition, the immune suppressing protein (e.g., 
VHv1.4 protein) is expressed, leading to the suppressing of 
the host immune system. As above, such a recombinant virus 
10 
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may also encode one or more toxic substances, to increase 
the speed and ef?cacy of the insect kill. 
In these and other embodiments of the invention, the 
parasitoid host range is broadened to include non-natural 
host insects. By “non-natural” it is meant that the host insect 
is not the naturally-occurring host for the particular 
endoparasitoid insect. 
Additionally, vectors under the invention may also encode 
a marker for the rapid identi?cation of recombinant virus, 
endoparasite, host or plant. Such a marker may provide a 
visible result (e.g., [3-galactosidase, luciferase, etc.) or may 
be either a positive or a negative selectable marker. 
The invention is exempli?ed by the VHv1.4 gene of the 
C. sonorensis/H. virescens parasitic system. It is by no 
means meant, hoWever, to be restricted to this system. For 
example, there are tens of thousands or insect species, many 
if not all of Which are expected to contain viruses that 
function analogously to the C. sonorensis polydnavirus in 
suppressing the host immune response. Moreover, certain 
toxins and oviduct proteins are also believed to have 
immune suppressing function. Each of these immune sup 
pressing proteins, Which may be related by a common 
cysteine motif (Dib-Hajj et al., Proc. Natl. Acad. Sci. (USA) 
90: 3765 (1993)), are Within the scope of the invention. 
Representative insect species that may be biologically 
controlled by the process of the invention include: 
Autographica californica, Heliothis virescens, Heloithis 
Zea, Spodoptera frugipera'a, Peria'roma saucia, Prode 
nia eridonia, Prodenia ornithogalli, Pseua'aletia 
unipuncia, Spodoptera exigua, Trichoplusia ni, Agrotis 
ipsilon, Estigmene acrea, malacosoma pluviale, 
Nomophila noctuella, Pieris rapae, Proa'enia prae?ca, 
Ceramica picta, Dargida procincm, Feltia sp., Gra 
pholithya molesta, Heliothis armigera, Heliothis 
assulta, Hymenia recurvalis, Lacinipolia stricta, Mis 
elia sp, Morrisonia confusa, Neleucania sp., Neuris sp., 
Plusia sp., Ostrinia nubilalis, Vanessa atalanta and the 
like. 
Similarly, representative endoparasitoids Which may be 
genetically modi?ed or Which may carry genetically modi 
?ed virus under the invention include those of the order 
Hymenoptera, particularly of the families Braconidae and 
Ichneumonidae. 
As Will be appreciated by those skilled in the art, the 
invention provides for protection of one or more crops. Most 
notable as the commercially important crops protected are 
corn (maiZe), sorghum, beet, cotton, tomato, tobacco, 
sun?oWer, soybean, rapeseed, groundnuts, chick pea, 
saf?oWer, beets, cabbage, broccoli and cauli?oWer and the 
like. 
As previously noted, the invention as presently disclosed 
is exempli?ed by the C. sonorensis polydnavirus VHv1.4 
gene and protein product, as Well as biologically active 
fragments thereof. Such a biologically active fragment pref 
erably contains at least one of the above-mentioned cysteine 
motifs. Another biologically active fragment, for example, is 
the protein product produced devoid of the hydrophobic 
N-terminal sequences and DNA encoding such a protein. 
Additionally, a homolog of the DNAs and proteins of the 
invention are Within the scope of the claims appended 
hereto. Such a DNA homolog, for example, is one that 
makes use of the degeneracy of the genetic code to provide 
a DNA of differing sequence from that disclosed herein by 
that at the same time encodes the same, or substantially the 
same, protein product. 
As discussed above, the VHv1.4 gene encodes tWo cys 
teine motifs. Based upon these motifs, one of ordinary skill 
5,827,518 
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in the art can design probes to search for other members of 
this gene family in other viruses, insect hosts and other 
species (eg arachnids). Such genes can be screened for 
immune suppressing activity, for example as detailed above, 
and used in the methods under the invention in a fashion 
analogous to the use of the VHv1.4 gene exempli?ed herein. 
Such immune suppressing genes may also be used in com 
bination under the practice of the invention, to create numer 
ous immune suppressing products for the control of insect 
pests. 
It is a further aspect of the invention, then, to use the 
immune suppressing VHv1.4 gene in combination With 
other genes that affect an immune-suppressing response. 
When used in such a combination, the host range for a given 
parasitoid may be even more greatly expanded. Examples of 
10 
10 
such other genes are given above and include those analo 
gous immune-suppressing genes from other parasitoid/host 
systems and other species under the invention. Such com 
binations of genes may be encoded, for example, in a single 
vector, on separate vectors, or incorporated into the virus, 
parasitoid and/or plant genome. 
The above examples are meant to be exemplary of the 
invention, and should not be construed as a limitation to the 
claims appended hereto. Moreover, the scope and spirit of 
the invention as de?ned in the claims is meant to encompass 
those variants thereof Which are obvious to those of ordinary 
skill in the art in light of the disclosure contained herein. 
Publications and patents cited above are each incorpo 
rated herein in their entirety by reference thereto. 
SEQUENCE LISTING 
( 1 ) GENERAL INFORMATION: 
( i i i )NUMBER OF SEQUENCES: 8 
( 2 ) INFORMATION FOR SEQ ID NO:1: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 2310 base pairs 
( B ) TYPE: nucleic acid 
( C ) STRANDEDNESS: double 
( D ) TOPOLOGY: unknown 
( i i )MOLECULE TYPE: DNA (genomic) 
' i i )HYPOTHETICAL:NO 
' v )ANTI-SENSE: N0 
i ) ORIGINAL SOURCE: 
( A ) ORGANISM: Campoletis sonorensis virus 
( v i i )IMIVEEDIATE SOURCE: 
( B ) CLONE: VHv1.4 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:1: 
GCTATCGCGA TACAATTTCC AGCTAAATTA 
GAGGCCAGCT 
GTATTACTTA 
ATCCAATTTG 
GCCATTTCAT 
CATTACCTGG 
GCATCCTGTG 
CGAGCCAGGG 
ACAAACCATT 
ATGATGGAGA 
AAATTCAATT 
CTGCCGACTT 
ATTCTTCGGC 
ATTGAGTGCA 
TATAAAGCAC 
ACTGGGTGCT 
TCGCGGCCTG 
TTCGTAGATA 
AATTAAATAC 
ACCATGAAGT 
GTCGAGACAT 
TGCATCGGCA 
GGAGCATATG 
TGTCTACTTT 
AAGATAATAT 
GAAGATCGCA 
GGACTCTGTG 
CAATTGAACG 
ACGCTGGGAA 
TACATGTATA 
CGCGTCGGAC 
GTTGTGGACT 
AATGTTTTAT 
TTTTGTGGTT 
CAACTGAGAA 
ATTACCAACC 
CCTGCTGAAA 
ATATATTGGA 
TGTCTTGTAT 
CATCGGTGCA 
CCCCATTAGA 
AAACTAATTT 
TCAAGCCAGA 
TCGTTAGGTC 
AAAGCACAGT 
AATTTTTTCA 
AATCCTTCTT 
TTGTTACTAT 
TGCACTGGTC 
AGAGGCCGAC 
TGTAAGTACA 
CTCTTTACCG 
ATAGAATATC 
GTTTCAGTGC 
ATTTGGACGT 
CGTCATAAAC 
GGCGGAACTC 
ACCCAAGATA 
GTCCGGGTCA 
CCCGCCCTCA 
TTGTAAGTAT 
CGTAACCGTC 
TCGCAGATAA 
GCAGTGGTTA 
GGGAAAACTT 
TCATTGCTAG 
ACGAATGTGT 
TATACCTAAC 
ATTGAGTCGA 
AAAGAGTACA 
AACCTTACAC 
TCCAATCTGT 
GAAGACGCGG 
GCTCGAACGA 
ACAATCCAGA 
TTCATAAAAA 
GAATGAAGGA 
TAAATCATAG 
CAGTGGCTGC 
CGCCCCAATG 
CACTTTGTCA 
CGTTAGTGAG 
ATACCATGTC 
CGAAGCCCTG 
TCTGTGATCG 
TGTATAAAGA 
ATTTCCAAGG 
GAAAAGTCGA 
11 
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GGAAGTCGTG 
TGGAGACAAG 
TATTAACAAC 
ATATGCCTGG 
TACTTTATAT 
TAATATTGTC 
ATCGCACATT 
TCTATGCTCC 
TGAACGAAAC 
TGCCGGAATT 
AACTCGAGTC 
ATTATTCAAT 
CCACCACGCT 
CAGCATATAT 
TGAAGTAGAC 
ACTCTTAGTT 
ATTTTGTATA 
TCGCTGGTTC 
CACCATTCGA 
GAATCGATCA 
GTTTTTCAAC 
TGTTGCATTA 
TGTCGTTGAA 
TTTTTTCAAT 
AAACAGAGTA 
ACAGTATCCG 
AAACCTGTAA 
CTGAAACTCT 
ATTGGAATAG 
TTGTATGTTT 
GGTGCAATTT 
ATTAATAGTC 
TAAATTGTCG 
CAAGCCAGAA 
ACAGTGCATC 
CGTTCAAGCA 
GAAACCCTCC 
TGGAATAGGC 
ATCGTCACGT 
ATTCTCAATC 
TTTTCAGTGC 
ATCTAAACCC 
TGGCTAACCA 
AGAAGGAAGT 
TGAGCTAGAG 
AGCATTTTTT 
AAACTATTTA 
AAAGAGTAAT 
( 2 ) INFORMATION FOR SEQ ID NO:2: 
CGGACAACAT 
GAACAGAAAA 
GTACATCATT 
TTACCGACGA 
AATATCTATA 
CAGTGCATTG 
GGACGTGAAG 
GTTAACAACT 
AATCTCAGCG 
TCCAAGATAG 
CCAAATTATG 
TATGACTGAT 
GAAGATGCTG 
ATCGTGTACT 
TTTATCTCTG 
TGTCGTCGTG 
GTGAATTCGA 
CGTAATTTCG 
ATTGGATATT 
TTACGCTGTC 
GTGGTTCTTG 
GAAATTTTGT 
GTTTATTATA 
GATAATTAAA 
( i )SEQUENCE CHARACTERISTICS: 
A i i ) MOLECULE TYPE: cDNA 
( i i i )HYPOTHETICAL:NO 
A 
A 
GCTATCGCGA 
GAGGCCAGCT 
GTATTACTTA 
i X )FEATURE: 
( A )NAME/KEY: CDS 
( B )LOCATION: 190.1155 
TACAATTTCC 
ACTGGGTGCT 
TCGCGGCCTG 
ACCTGGACC ATG AAG TTT 
Met Lys Phe 
1 
( A ) LENGTH: 1472 base pairs 
( B ) TYPE: nucleic acid 
( C ) STRANDEDNESS: double 
( D )TOPOLOGY: unknown 
x i ) SEQUENCE DESCRIPTION: SEQ ID NO:2: 
AGCTAAATTA 
TACATGTATA 
CGCGTCGGAC 
GAAATTGAGT 
CTGGGTACAA 
GTTAGCACTT 
ATATGTCGTA 
TCTAACATAC 
AGTCGAAGGA 
AGGACATCTA 
CCACACTGTA 
ATTGGTATAT 
AAGATGAGCG 
AACTGGTAAG 
GGAACTCCCC 
GCGACAGATG 
TTTCCACATG 
GGAGAGTCTG 
GATCTTGTGA 
AGAGGCCGTG 
TATGCGGTCT 
CGCTGGAAGG 
GACTTTTCAT 
TTTTATACGA 
CTTTCCTTAT 
AGAAGGAATA 
ACCGAAGCCG 
TCCCCAGACA 
TGTCAACAAA 
AGTGAGATGA 
CATGTCAAAT 
GTCCCGCTGC 
TGGTCGATTC 
TTTAGAATTG 
AGCAGCAGCT 
AAAATCCCCA 
TAAATAATGG 
AACAAAATGT 
CCTTTGACGA 
TCACGCCCTT 
TGAGCAATTT 
ACTTGAACTA 
TTGCTGGGAG 
ACACGGCCGA 
TCGACAGGTT 
CAACAAGGAC 
ATATTTTTTA 
ATCAATAATT 
ATGTAATATG 
AACGTGAACC 
CGGATTCGCC 
CCATTGGAGC 
TGGAGATGCC 
TCAATTAAGA 
CGACTTGAAA 
CTCGGCGGGA 
AGTAAAGGAA 
GTAATCCCCA 
GAAGCCCCAG 
ATACCACTTC 
ATGTTTTATG 
TGAACGATTA 
TAACATGTAT 
CACGGGGTAC 
CAT CAATGTC 
AATAAGCTGT 
AGCTACTGTT 
AAGGGAACAA 
CACTTTTTCC 
ATGTCTTTTG 
TTAGGTTGCA 
TTTCAAGATT 
TCGTTAGGTC GTCCGGGTCA GCTCGAACGA 
AAAGCACAGT CCCGCCCTCA ACAATCCAGA 
AATTTTTTCA TTATAATAAA TCATAGCATT 
TTG TGG TTT GCA CTG GTC GCA GTG GTT ACA 
Len Trp Ph 
5 
e Ala Len VaI Ala 
10 
Val VaI Thr 
GTG GCT GCG CAT CCT GTG GTC GAG ACA TCA ACT GAG AAA GAG GCC GAC 
VaI Ala 
15 
AIa His Pro Val Val 
20 
GIu Thr Ser Thr Glu 
25 
Lys GI u AIa Asp 
60 
120 
180 
228 
276 

15 
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TCTTTTGTGT TGCATTAAGC ATTTTTTGAA ATTTTGTCTT TCCTTATATC AATAATTTTA 
GGTTGCATGT CGTTGAAAAA CTATTTAGTT TATTATAAGA AGGAATAATG TAATATGTTT 
CAAGATTTTT TTTCAATAAA GAGTAATGAT AATTAAA 
( 2 ) INFORMATION FOR SEQ ID NO:3: 
w 
( i )SEQUENCE CHARACTERISTICS: 
Th 
Ph 
21 
PI 
29 
( A ) LENGTH: 322 amino acids 
( B )TYPE: amino acid 
( D )TOPOLOGY: IineaI 
' i ) MOLECULE TYPE: protein 
i ) SEQUENCE DESCRIPTION: SEQ ID NO:3: 
H 
I 
Ph 
Ln: 
6 
As 
10 
Th 
O 
Ph 
Th 
Th 
Th 
AI 
15 
Ph 
6 
6 
Ala 
Asn 
295 
Th 
Th 
AI 
20 
As 
28 
m 
AI 
26 
Ph 
Se 
14 
As 
22 
GI 
30 
000 
O 
O 
Th I 
Ln: 
I 
Th 
Ph 
Me 
Se 
16 
in 
O 
1375 
1435 
1472 
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( 2 ) INFORMATION FOR SEQ ID NO:4: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 882 base pairs 
( B ) TYPE: nucleic acid 
( C ) STRANDEDNESS: double 
( D )TOPOLOGY: unknown 
A i i ) MOLECULE TYPE: cDNA 
( i i i )HYPOTHETICAL:NO 
A i v )ANTI-SENSE: NO 
A v i )ORIGINAL SOURCE: 
( A ) ORGANISM: Campoletis sonorensis virns 
( i X )FEATURE: 
( A )NAME/KEY: CDS 
( B )LOCATION: 127.319 
( x i )SEQUENCE DESCRIPTION: SEQ ID NO:4: 
GTCGAACTGT ATCTCTAACG ATCACAGTAG CTCAACCCAA ACTTTTCAAA ATTTTCGCAA 
AAATCTGTTT TTTGGTGCTT ATGTGTTGCG TGTTCGTCTA TAAAAACATC AATTTGTAAA 
CAATTG ATG TAC AAA TTT GTT TTG GTG ACG CTT CTG AGC TGT GTG CTG 
Met Tyr Lys Phe Va I Len Va I Thr Len Len Ser Cys Va I Len 
1 5 10 335 
GCC CAA GCG AAT CCG CAG GTG TCG CGC CAT GGT CCC GCT GCT GTT GTA 
AI a GIn AI a Asn Pro GIn Va I Ser Arg Hi s GI y Pro AI a AI a Va I Va I 
15 2O 25 3O 
TCG GAT GCG AAT CGA ACG GTT CAT CCT CCA CCA GCT CAA AAC CAC GCC 
Ser Asp A1 a Asn Arg Thr Va I Hi 5 Pro Pro Pro A1 a GIn Asn Hi 5 A1 a 
35 4O 45 
GAG ATG GCA CGT TTC ATC GTT AAT CAA GCC GAC TGG GCA TCT CTG GCA 
GIn Me I AI a Arg Phe I I e Va I Asn GIn AI a Asp Trp AI a Se r Len AI a 
50 55 6O 
ACA ATC AGC ACT ATA GAA AAC ATC GCT TCT TAT CCA ATT GCC AGC 
Thr I I e Ser Thr I I e GIn Asn I I e AI a Ser Tyr Pro I I e AI a Ser I I e 
65 7O 75 
AAA TCA ATT AGT GAC GGA CCG GGC GGC AAT GGT ACC GGA GAT CCT TAT 
Lys Ser IIe Ser Asp GIy Pro GIy GIy Asn GIy Thr GIy Asp Pro Tyr 
80 85 9O 
TTG TTT ATC TCA CCG AGG ACT TTC TCT GGT AGA GAC ATA GTT GCT GAT 
Len Phe IIe Ser Pro Arg Thr Phe Ser GIy Arg Asp IIe VaI AIa Asp 
95 100 105 110 
TCG CGA GCG AGT CTC GTC ATC TCC TTG GCT CAG GGT GCC TAC TGC AAG 
Ser Arg AIa Ser Len VaI IIe Ser Len Ala GIn GIy AIa Tyr Cys Lys 
115 120 125 
GAA AAT AAT TAT GAT CCA ATG GAC CCG CGA TGC GGA AGA GTT GTC ATC 
GIn Asn Asn Tyr Asp Pro Met Asp Pro Arg Cys GI y Arg Va I Va I I I e 
130 135 140 
ACC GGG CCG AGC CGA AAA AAT TGG GGA ATC CAG CCT CCG AAT ACC GCA 
Thr GIy Pro Ser Arg Lys Asn Trp GIy IIe GIn Pro Pro Asn Thr AIa 
145 150 155 
AGA GCC AGG ACT GCT TTC TTC GGA CGT CAT CCC GCG ATG NCC TAT ATG 
Arg AI a Arg Thr AI a Phe Phe GI y Arg Hi s Pro AI a Me I Xaa Tyr Me I 
160 165 170 
CCT AGA GAT CAT GGT TTC TAC TTC GCG AAA ATA AAC ATT GAA AAT CTT 
Pro Arg Asp His GIy Phe Tyr Phe AIa Lys IIe Asn IIe GIn Asn Len 
175 180 185 190 
CGT GTT CTT GCA TCA TTT GGT CCA TTC CAC GTG GTC TCC GCT CAA GAT 
Arg VaI Len AIa Ser Phe GIy Pro Phe His VaI VaI Ser AIa GIn Asp 
195 200 205 
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TAC TAC AGT GCA TCG GTT GGA CAG CGA CAA GAT TGN ATG TAT TCA CTA 
Tyr Tyr Se r Al a Ser Va 1 GI y Gln Arg Gl n Asp Xaa Me I Tyr Ser Len 
210 215 220 
TAT ACG AGT GTA CAA ATT GCA CTT CGG TAATTTGAGA AAGTTCAATC 
Tyr Thr Ser Val Gln Ile Ala Len Arg 
225 230 
ATATTTGACT CTCCGAGGAA CNCGATACTG TTGAAATAAA ATC 
( 2 ) INFORMATION FOR SEQ ID NO:5: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 231 amino acids 
( B )TYPE: amino acid 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: protein 
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:5: 
Me I Tyr Lys Phe Va 1 Len Va 1 Thr Len Len Ser Cys Va 1 Len Al 
1 5 1O 15 
130 135 14 O 
155 16 O 
18 190 
( 2 ) INFORMATION FOR SEQ ID NO:6: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 21 base pairs 
( B ) TYPE: nucleic acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i ) MOLECULE TYPE: other nucleic acid 
( A ) DESCRIPTION: /desc = “PRIIVEER’7 
5,827,518 
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( i i i )HYPOTHETICAL:NO 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:6: 
GGTGGCGACG ACTCCTGGAG C 
( 2 ) INFORMATION FOR SEQ ID NO:7: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 17 base pairs 
( B ) TYPE: nucleic acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i ) MOLECULE TYPE: other nucleic acid 
( A ) DESCRIPTION: /desc = “PRIlVLER’7 
( i i i )HYPOTHETICAL:NO 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:7: 
GACACCAACT GGTAATG 
( 2 ) INFORMATION FOR SEQ ID NO:8: 
( i )SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 26 base pairs 
( B ) TYPE: nucleic acid 
( c )STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i ) MOLECULE TYPE: other nucleic acid 
( A ) DESCRIPTION: /desc = “PRIlVLER’7 
( i i i )HYPOTHETICAL:NO 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:8: 
GCACTTAACT TTTTTTTTTT TTTTTT 
21 
17 
26 
We claim: 
1. A recombinant DNA comprising SEQ ID NO: 1 or a 
biologically active fragment or homolog thereof, Wherein 
the encoded product suppresses the immune system of one 
or more insect species. 
2. The recombinant DNA according to claim 1, Wherein 
said DNA is isolated from the C. sonorensis polydnavirus. 
3. A method of inhibiting the immune response of a host 
insect comprising: 
providing a bacterial expression vector or recombinant 
baculovirus containing the DNA according to claim 1 
operably linked to one or more expression signals; and 
introducing the bacterial expression vector or recombi 
nant baculovirus and one or more endoparasitoid insect 
eggs into said host insect, 
Whereby said DNA is expressed thereby inhibiting the 
immune response of said host insect. 
4. A vector comprising the recombinant DNA according 
to claim 1. 
5. A recombinant DNA encoding SEQ ID NO: 3 or a 
biologically active fragment thereof, Wherein the encoded 
product suppresses the immune system of one or more insect 
species. 
6. The recombinant DNA according to claim 5, Wherein 
said DNA is isolated from the C. sonorensis polydnavirus. 
7. A method of inhibiting the immune response of a host 
insect comprising: 
providing a bacterial expression vector or recombinant 
baculovirus containing the DNA according to claim 5 
operably linked to one or more expression signals; and 
introducing the bacterial expression vector or recombi 
nant virus baculovirus and one or more endoparasitoid 
insect eggs into said host insect, 
Whereby said DNA is expressed thereby inhibiting the 
immune response of said host insect. 
8. A vector comprising the recombinant DNA according 
to claim 5. 
9. The vector according to claim 8, further comprising at 
least one DNA sequence encoding a toxin. 
10. The method of claim 7, Wherein said DNA is isolated 
from the C. sonorensis polydnavirus. 
11. The method of claim 7, Wherein said insect eggs are 
55 from C. sonorensis. 
12. The method of claim 3, Wherein said DNA is isolated 
from the C. sonorensis polydnavirus. 
13. The method of claim 3, Wherein said insect eggs are 
from C. sonorensis. 
14. The vector according to claim 4, further comprising at 
least one DNA sequence encoding a toxin. 
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